Cash on Hand for Quest Diagnostics (DGX)
According to Quest Diagnostics's latest reported financial statements, the company's latest reported cash and short-term investments is $393.00M USD. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for a net cash/debt picture and with total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingCash on HandSwitch metric
Latest period
$393.00M
YoY change
-23.5%
5Y CAGR
-18.4%
Peak year (2019)
$1.19B
Latest annual
$420.00M
Cash on Hand history chart for Quest Diagnostics (DGX) from 1996 to 2025
Cash on Hand history table for Quest Diagnostics (DGX) from 1996 to 2025
| Fiscal year | Period ended | Reported | Cash on Hand | YoY |
|---|---|---|---|---|
| 2025 | $420.00M | -23.5% | ||
| 2024 | $549.00M | -20.0% | ||
| 2023 | $686.00M | +117.8% | ||
| 2022 | $315.00M | -63.9% | ||
| 2021 | $872.00M | -24.7% | ||
| 2020 | $1.16B | -2.9% | ||
| 2019 | $1.19B | +783.0% | ||
| 2018 | $135.00M | -1.5% | ||
| 2017 | $137.00M | -61.8% | ||
| 2016 | $359.00M | +169.9% | ||
| 2015 | $133.00M | -30.7% | ||
| 2014 | $192.00M | +2.7% | ||
| 2013 | $187.00M | -36.7% | ||
| 2012 | $295.60M | +79.3% | ||
| 2011 | $164.90M | -63.3% | ||
| 2010 | $449.30M | -15.9% | ||
| 2009 | $534.30M | +110.4% | ||
| 2008 | $253.90M | +51.5% | ||
| 2007 | $167.59M | +12.0% | ||
| 2006 | $149.64M | +62.4% | ||
| 2005 | $92.13M | +25.7% | ||
| 2004 | $73.30M | -52.7% | ||
| 2003 | $154.96M | +60.1% | ||
| 2002 | $96.78M | -20.9% | ||
| 2001 | $122.33M | -28.7% | ||
| 2000 | $171.48M | +528.1% | ||
| 1999 | $27.30M | -86.5% | ||
| 1998 | $202.90M | +25.5% | ||
| 1997 | $161.70M | +285.4% | ||
| 1996 | $41.96M | — |
Cash on Hand values are taken from Quest Diagnostics's reported balance sheets (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Quest Diagnostics (DGX) most recent annual cash and short-term investments stands at $420.00M (2025) – declined 23.5% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Quest Diagnostics cash and short-term investments compounded at -18.4% per year, with a net decline across the window.
Quest Diagnostics cash and short-term investments peaked at $1.19B in 2019; the latest annual figure is $420.00M in 2025 (64.8% below peak).
$1.19B stands as the all-time-high annual cash and short-term investments, posted in 2019, against a low of $27.30M during 1999.
Quest Diagnostics (DGX) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $11.85B.
Quest Diagnostics Cash on Hand by Year
Quest Diagnostics Cash on Hand 2025: $420.00M
Quest Diagnostics cash and short-term investments in 2025 was $420.00M, declined 23.5% below 2024.
Quest Diagnostics Cash on Hand 2024: $549.00M
Quest Diagnostics cash and short-term investments in 2024 was $549.00M, declined 20.0% below 2023.
Quest Diagnostics Cash on Hand 2023: $686.00M
Quest Diagnostics cash and short-term investments in 2023 was $686.00M, surged 117.8% from 2022.
Quest Diagnostics Cash on Hand 2022: $315.00M
Quest Diagnostics cash and short-term investments in 2022 was $315.00M, plunged 63.9% below 2021.
Quest Diagnostics Cash on Hand 2021: $872.00M
Quest Diagnostics cash and short-term investments in 2021 was $872.00M.
See more financial history for Quest Diagnostics (DGX).
Sector peers — Cash on Hand
Companies in the same sector as Quest Diagnostics, ranked by their latest cash and short-term investments.
| Company | Cash on Hand | Sector |
|---|---|---|
| UnitedHealth Group Incorporated (UNH) | $28.12B | Healthcare |
| Novo Nordisk A/S (NVO) | $26.96B | Healthcare |
| Johnson & Johnson (JNJ) | $20.10B | Healthcare |
| Merck & Co., Inc. (MRK) | $14.56B | Healthcare |
| Amgen Inc. (AMGN) | $9.13B | Healthcare |
| Eli Lilly and Company (LLY) | $7.27B | Healthcare |
| AstraZeneca PLC (AZN) | $5.74B | Healthcare |
| AbbVie Inc. (ABBV) | $5.26B | Healthcare |
Frequently asked questions
What is Quest Diagnostics's cash and short-term investments?
- Latest reported cash and short-term investments for Quest Diagnostics (DGX) is $393.00M (period ending March 31, 2026).
How has Quest Diagnostics cash and short-term investments changed year-over-year?
- Quest Diagnostics (DGX) cash and short-term investments changed -23.5% year-over-year on the latest annual filing.
What is the long-term growth rate of Quest Diagnostics cash and short-term investments?
- Quest Diagnostics (DGX) cash and short-term investments compound annual growth rate is -18.4% over the most recent 5 years available.
When did Quest Diagnostics cash and short-term investments hit its highest annual value?
- Quest Diagnostics cash and short-term investments reached its highest annual value of $1.19B in 2019.
What was Quest Diagnostics cash and short-term investments in 2024?
- Quest Diagnostics (DGX) cash and short-term investments in 2024 was $549.00M.
What was Quest Diagnostics cash and short-term investments in 2025?
- Quest Diagnostics (DGX) cash and short-term investments in 2025 was $420.00M.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
DGX Overview
Company profile, financial tools, and key metrics
DGX Revenue Counter
Earns $357.62 every second. See per minute, hour, and day.
DGX Earnings Counter
Earns $32.47 per second net profit. See per minute, hour, and day.
DGX Economic Scale
Exceeds Monaco's GDP. Compare with world economies.
DGX What If Invested
What if you had invested $1,000? See historical returns from any date.
DGX How It Makes Money
Discover visual breakdown of $11.28B in revenue — where it comes from and where it goes.
DGX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
DGX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
DGX Daily Price Character
Steady · 50.6% historical win rate (green days). Streaks & record days.
DGX Buybacks
2.09% TTM buyback yield. Shareholder yield & SBC comparison.
DGX Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.
DGX Dividend Profile
Yield: 1.72%. Safety: 5/8. See full history.
DGX Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
DGX Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.